🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In ~1000 40-65 yr olds w/ a 10-yr risk of <5% prevalence of coronary athero was 36% (51%♂️; 24%♀️) & 3.4% had ≥1 high-risk plaque feature. Lp(a) was one of the highest associated w/ atherosclerosis demonstrating an adj odds ratio of 1.46 #knowLpa jacc.org/doi/10.1016/j.…

Very important analysis! ➡️ Even in seemingly low risk patients, atherogenic lipoproteins (LDL and Lpa) are key drivers of atherosclerosis. #LDLSafeZone #KnowLpa @TheFHFoundation National Lipid Association ASPC Matthew Budoff MD Khurram Nasir Jonathan Fialkow Preventive Cardiovascular Nurses Association

NEW ANALYSIS: Published in the JACC Journals, new data showing that when there was atherosclerosis in "low risk" asymptomatic individuals, the key drivers were LDL-C and Lp(a). #KnowFH #KnowLpa #LDLSafeZone jacc.org/doi/10.1016/j.…

One of the biggest barriers to Lp(a) testing is uncertainty regarding what to do with an elevated level. In this review, star UCSD Internal Medicine Residency resident Charlotte Ellberg and I outline current management strategies #KnowLpa journals.lww.com/co-lipidology/…

Our editorial in #EJPC discussing a recent study on the association of Lp(a) with ISR after PCI, highlighting the importance of Lp(a) in secondary prevention populations. European Society of Cardiology Journals UC San Diego Cardiology UC San Diego Cardiology Fellows UC San Diego Health Sciences academic.oup.com/eurjpc/advance…

Ready to travel, but no place to go. Thank you to HFSA for making the difficult but right decision. Robert Mentz, MD Anu Lala-Trindade there should be a picture collage of everyone wearing their purples!

Here is a paper on heart failure linking Lp(a) and Sam Tsimikas to outcomes. This may be mediated via a lncRNA that induces myocardial fibrosis. More to come on this story. @JJheart_doc Pradeep Natarajan ncbi.nlm.nih.gov/pubmed/38860394

Higher Lp(a) levels were associated with increased progression of coronary plaque burden and increased presence of low-density noncalcified plaque and pericoronary adipose tissue inflammation. ja.ma/3BoACQ5

Our new expert consensus document justifies why Indian and other South Asian patients at extreme ASCVD risk need to have LDL-C targets of 30 mg/dl and even lower to 10-15 mg/dl in those still suffering recurrent events.

An estimated 1.19 million deaths per year could be prevented with optimal implementation of GDMT for heart failure with reduced ejection fraction globally. @GCFMD ja.ma/3NaKb7C

"This is why you come to Oregon." #GoDucks

Lipoprotein, Lp(a) and LDL-cholesterol, LDL-C, are independent and additive for cardiovascular risk. Reduction in LDL-C cannot fully offset Lp(a)-mediated risk suggesting a need for targeted therapy for both. Peter Willeit Harpreet Bhatia @Lpa_doc ahajournals.org/doi/abs/10.116…

#AHA24: How does OxPL-apoB affect the risk of calcific aortic valve disease? Using data from MESA, Drs. Harpreet Bhatia, Sam Tsimikas, MD & team show that ⬆️ OxPL-apoB is associated with increased incidence and progression of valve disease bit.ly/3YRMeDf #JACC

#AHA24 ICYMI: #JACC AE Dr. Marc Bonaca MD MPH and Dr. Sam Tsimikas, MD discuss new insights from the MESA cohort about OxPL-apoB and risk for calcific aortic valve disease 👇 📄: bit.ly/3YRMeDf

In our new study in EJPC, optimal CVD risk factor control was a/w lower risk across Lp(a) levels, though residual risk remains. These results show the importance of aggressive risk factor mgmt in patients with elevated Lp(a). Alexander C. Razavi Sam Tsimikas, MD academic.oup.com/eurjpc/advance…

This picture is so profound. With 10 years of working in the ICU, there were several times when it felt like just because we can doesn’t mean we should. As one nurse put it “you’re slapping back the hand of Jesus” - the crocs are a nice added touch to the picture BTW

Just published: 🫀Coronary Artery Calcium Scoring in the Context of Widespread Lipoprotein(a) Testing: Clinical Considerations and Implications for Lipid-Lowering Therapies🔬 🚨 New insights from Palanisamy, Burka & Blaha (2025) show Lp(a) & CAC aren’t just independent risk

Knowledge is power, especially for your heart!🫀 Lipoprotein(a) [Lp(a)] is a genetic risk factor for heart disease & stroke. Identifying high Lp(a) levels early can help individuals take proactive steps to protect their #hearthealth. 📃Learn more: learnyourlipids.com/lipid-disorder…

The Multi-Ethnic Study - MESA - 🤔"Group 1 LDL-C, mg/dL (SD) : 82.8 (14.6) Lp(a), mg/dL (IQR): 11.1 (5.1–22.2)" 🤔"Group 2 LDL-C, mg/dL (SD) : 131.5 (23.1) Lp(a), mg/dL (IQR): 14.3 (7.4–25.6)" 👉"Group 3: LDL-C≤100, Lp(a) ≥ 50" 👉"Group 4: LDL-C > 100, Lp(a) ≥ 50"

Cardio Town Hall: Amyloidosis is June 12, get prepared with NEW CardioBites+: Amyloidosis to learn the different mechanisms of disease and why understanding these differences may impact management decisions for these patients. 13-minute watch >> youtu.be/Fzq7DPIlg_A